BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

San Mateo, Calif., United States:   Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with

READ MORE